A nomogram to predict pathologic T2 stage in candidates to robot-assisted radical prostatectomy with iT3 prostate cancer on preoperative multiparametric MRI: results from a multi-institutional collaboration.

Journal: Minerva urology and nephrology
PMID:

Abstract

In candidates to robot-assisted radical prostatectomy (RARP) for locally advanced (iT3) prostate cancer on preoperative MRI, the performance of MRI for local staging is demonstrably suboptimal, and currently no prediction tools that might help surgeons in preoperative planning are available. We analyzed data of 685 patients with iT3 prostate cancer (PCa) who received RARP at five participating institutions between 2012 and 2020. Multivariable logistic regression model investigated predictors of pT2 disease among variables available before surgery (i.e.: preoperative PSA, biopsy ISUP group, clinical T stage on digital rectal examination-DRE, prostate volume on MRI, PIRADS score of index lesion, seminal vesicles invasion on MRI, location suspicious for T3 disease on MRI). Coefficients from such model were used to build a nomogram to predict organ-confined (i.e. pT2) disease on final pathology. Internal validation was performed using the leave-one-out cross-validation. Median (interquartile range) preoperative PSA was 7.5 (5.2, 11.9) ng/mL, and 280 (41%) and 216 (32%) had biopsy ISUP group 4-5 disease and palpable disease on DRE, respectively. Preoperative MRI was suspicious for iT3 disease on the mid-posterior part of the gland in 485 (71%) men, and 527 (77%) men had a PIRADS 5 lesion. After surgery, a total of 192 (28%) patients had organ-confined disease (i.e. pT2). All variables fitted into the model and were considered to build the nomogram. After internal validation, the AUC was 73% (95% confidence interval: 69%, 77%). Awaiting external validation, we provided data that is relevant to optimize surgical strategy in men diagnosed with iT3 PCa who are scheduled for RARP.

Authors

  • Carlo A Bravi
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: carloandrea.bravi@gmail.com.
  • Elio Mazzone
    Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium; ORSI Academy, Melle, Belgium.
  • Paolo Dell'Oglio
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
  • Marcio Covas Moschovas
    Global Robotics Institute, Advent Health, Celebration, FL, USA.
  • Alberto Martini
    University of Genoa, Italy.
  • Giuseppe Rosiello
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Pietro Piazza
    Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Angelo Mottaran
    Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna.
  • Marco Paciotti
    Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Luca Sarchi
    Department of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy. Electronic address: 279948@studenti.unimore.it.
  • Stefano Puliatti
    Urology Department, University of Modena and Reggio Emilia, Modena, Italy.
  • Sophie Knipper
    Martini-Klinik Prostate Cancer Center, Hamburg, Germany.
  • Ruben De Groote
    ORSI Academy Melle Belgium.
  • Riccardo Schiavina
    1 Department of Urology, University of Bologna , Bologna, Italy .
  • Bernando Rocco
    Department of Urology, Humanitas IRCCS Research Hospital, Rozzano, Milan, Italy.
  • Antonio Galfano
    Department of Urology, Ospedale Niguarda Ca' Granda, Milan, Italy.
  • Alberto Briganti
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Francesco Montorsi
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Vipul Patel
    Global Robotics Institute, Florida Hospital Celebration Health, Celebration, FL, USA.
  • Alexandre Mottrie
    ORSI Academy Melle Belgium.